Press releases
3 September 2021, Zwingenberg

Capital Markets Day BRAIN Biotech AG: Focus on BEC Technology and its Transformational Potential

  • Significant economic value potential for BRAIN
  • BEC already today a viable alternative in industrial biotechnology
  • Additional fields of application for BEC in development

The biotechnology group BRAIN Biotech AG informed investors about important developments in the company as part of a "Capital Markets Day". The focus was on BEC technology and its potential for the company.

BRAIN Biotech sees significant commercial potential in its proprietary genome editing technology, BRAIN Engineered CAS (BEC). This technology platform has good prospects to contribute to dynamic revenue growth in the service business (TMS) as a "We CRISPR for you" service. In addition, BEC will accelerate proprietary developments from BRAIN’s incubator, be used to develop highly efficient microbiological production strains, and offer the opportunity to build-up a lucrative licensing business.

Given the importance of BEC for the development of the company, the first step will be to create a flexible unit within BRAIN Biotech AG that will focus exclusively on the further development and partnering of this genome editing technology. In a second step, the technology will be carved out into a separate company. This will allow for maximum agility in research and enable flexible financing alternatives along the expansion path on the range of applications.

Lukas Linnig, CFO BRAIN Biotech AG, states: „The BEC technology is based on a proprietary CRISPR-Cas9-independent nuclease and can be employed for precise genome editing. With this proprietary development, BRAIN achieves freedom to operate from existing patents and can therefore use this technology cost-effectively for its own developments as well as aim to develop a profitable licensing business. In addition, we use BEC in service activities for our customers. Our proprietary genome editing nuclease enables BRAIN to actively participate in a market with strong growth and great influence on a sustainable biology based industrial production.”

Looking for additional strategic cooperation partners

In addition to the exclusive partnership for the use of the BEC technology in plants and the development in the field of life sciences announced in July together with Sartorius, BRAIN Biotech is actively striving for a partnering strategy in order to develop new fields of application, such as health care or diagnostics. Adriaan Moelker, CEO of BRAIN Biotech AG, says: "Strong partners are essential for us to quickly and purposefully introduce new applications and products to the market which are based on our BEC. We will carefully consider when to partner to ensure that all of BRAIN’s stakeholders can participate in BEC’s economic potential to the full extend.”

CRISPR-Cas genome editing nucleases can be used to modify genetic material in cells by specifically altering genes and inserting them into the genome or removing them altogether. Scientists use this biotechnological gene-editing process to make plants more resistant to pests or drought, for example, or to produce biological fuels. In biopharmaceuticals, gene scissors can lead to new therapies and improve the chances of curing a wide range of diseases such as cancer, neurodegenerative or hereditary diseases. Genome editing also has a wide range of applications in industrial biotechnology. Industry and academia alike are benefiting from an increasing variety of available genome editing tools.

Recorded presentations on the CMD 2021

Screenshots from BRAIN Biotech´s CMD presentations
© BRAIN Biotech AG

Press Image

Speakers at the CMD: CEO Adriaan Moelker (top left), CFO Lukas Linnig (bottom right) and the scientific heads of the genome editing program, Dr. Michael Krohn (top right) and Dr. Paul


BRAIN Biotech AG (“BRAIN”) is a leading European industrial biotechnology specialist with a focus on nutrition, health and the environment. As a technology and solutions provider the company supports the biologization of industries with bio-based products and processes. From contract R&D with industrial partners to advancing own disruptive incubator projects and customized enzyme products – BRAIN’s broad cutting-edge biotech expertise and its agile teams are key to success.

BRAIN Biotech AG, Germany, is the parent company of the international BRAIN Group, distributing specialty B2B products like enzymes or bioactive natural products. The BRAIN Group has its own fermentation or production facilities in Continental Europe, UK and the US, which together with the associated biotechnological solution competency complete the value chain within the group.

As a Participant of the United Nations Global Compact, BRAIN Biotech AG is committed to aligning strategies and operations with universal principles on human rights, labour, environment and anti-corruption and to actively advance common societal goals. Our products and services target at least five of the UN SDGs directly.

Since its IPO in 2016, BRAIN Biotech AG is listed in the Prime Standard of the Frankfurt Stock Exchange (ISIN DE0005203947 / WKN 520394).


This press release contains forward-looking statements. These statements reflect the current views, expectations, and assumptions of the management of BRAIN Biotech AG, and are based on information currently available to the management. Forward-looking statements are no guarantees of future performance, and entail both known and unknown risks as well as uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. Numerous factors exist that could influence the future performance by, and future developments at, BRAIN Biotech AG and the BRAIN Group. Such factors include, but are not limited to, changes in the general economic and competitive environment, risks associated with capital markets, currency exchange rate fluctuations, changes in international and national laws and regulations, in particular with respect to tax laws and regulations, as well as other factors. BRAIN Biotech AG does not undertake any obligation to update or revise any forward-looking statements.

Share this page